Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Dan Fuss Wins Outstanding Portfolio Manager at the 2019 U.S. Morningstar Awards for Investing Excellence



Reading Time: 5 minutes

  • Fixed income pioneer recognized for long-term track record
  • Fuss cited for advancing the next generation of fixed income investors
    at Loomis Sayles

CHICAGO–(BUSINESS WIRE)–Loomis, Sayles & Company, an affiliate of Natixis Investment Managers,
is pleased to announce that Dan Fuss has been named Outstanding
Portfolio Manager at the 2019 U.S. Morningstar Awards for Investing

Morningstar has granted annual awards to accomplished portfolio managers
since 1988. The awards recognize portfolio managers, asset management
firms, and up-and-coming managers who demonstrate excellent investment
skill, the courage to differ from the consensus to benefit investors,
and an alignment of interests with the strategies’ investors. The
Morningstar Awards for Investing Excellence winners are chosen based on
research and in-depth qualitative evaluation by Morningstar’s manager
research group. Methodology for the awards is available

“Dan Fuss pioneered the benchmark-agnostic, multisector approach to
fixed-income that has defined the firm’s flagship Loomis Sayles Bond
(LSBDX) since 1991. During his tenure at Loomis Sayles, he’s
demonstrated a value-driven, often contrarian, and aggressive strategy
that’s contributed to an impressive long-term record for the fund and
its siblings,” said Alfonzo Bruno, Manager Research Analyst at
Morningstar. “Fuss also deserves credit for working with firm CIO Jae
Park to codify the firm’s fixed-income investment process and to develop
the next generation of bond investors at Loomis Sayles.”

“We are honored that Morningstar has selected Dan as this year’s
Outstanding Portfolio Manager. He’s a true investment icon, but an even
better individual,” said Kevin Charleston, chief executive officer of
Loomis Sayles. “Since joining Loomis Sayles over 40 years ago, Dan’s
intellectual curiosity, investment excellence, humility and unparalleled
commitment to clients have shaped the ethos of our organization. As the
maverick of multisector investing, he has built an impressive team with
a suite of products all managed with a consistent investment philosophy
and a flexible, long-term, benchmark-agnostic, value-driven approach.”

Dan Fuss has 61 years of experience in the investment industry and has
been with Loomis, Sayles & Company since 1976. He is vice chairman of
the firm’s Board of Directors and co-manages the firm’s flagship Loomis
Sayles Bond Fund—which won the 2009 Morningstar Fund Manager of the Year
award in the fixed-income category—in addition to the Loomis Sayles
Investment Grade Fixed Income, Strategic Income, Fixed Income,
Institutional High Income and Global Allocation funds. In 2012, Dan
received both the Institutional Investor Money Management Lifetime
Achievement Award, and the Lipper Excellence in Investing Award. In
2013, Dan received the CFA Society of Milwaukee Lifetime Achievement
Award. In 2000, he was named to the Fixed Income Analysts Society’s Hall
of Fame in recognition of his contributions and lifetime achievements
toward the advancement of the analysis of fixed income securities and
portfolios. He has twice been president of CFA Society Boston. Dan
earned a BS and an MBA from Marquette University. He served in the US
Navy from 1955 to 1958 and held the rank of Lieutenant.

Since 1926, Loomis, Sayles & Company has
helped fulfill the investment needs of institutional and mutual fund
clients worldwide. The firm’s performance-driven investors integrate
deep proprietary research and integrated risk analysis to make informed,
judicious decisions. Teams of portfolio managers, strategists, research
analysts and traders collaborate to assess market sectors and identify
investment opportunities wherever they may lie, within traditional asset
classes or among a range of alternative investments. Loomis Sayles has
the resources, foresight and the flexibility to look far and wide for
value in broad and narrow markets in its commitment to deliver
attractive sustainable returns for clients. This rich tradition has
earned Loomis Sayles the trust and respect of clients worldwide, for
whom it manages $263.5 billion** in assets (as of March 31, 2019).

*Total strategy assets include all assets managed by the respective

**Includes the assets of Loomis, Sayles & Co., LP, and
Loomis Sayles Trust Company, LLC. Loomis Sayles Trust Company is a
wholly owned subsidiary of Loomis, Sayles & Company, LP.

Natixis Investment
Managers serves financial professionals with more insightful ways to
construct portfolios. Powered by the expertise of more than 20
specialized investment managers globally, we apply Active Thinking®
to deliver proactive solutions that help clients pursue better outcomes
in all markets. Natixis ranks among the world’s largest asset management
firms1 ($917.1 billion/€802.1 billion AUM2).

Natixis Investment Managers includes all of the investment management
and distribution entities affiliated with Natixis Distribution, L.P. and
Natixis Investment Managers S.A. Not all offerings available in all

1Cerulli Quantitative Update: Global Markets 2018
ranked Natixis Investment Managers as the 16th largest asset manager in
the world based on assets under management as of December 31, 2017.

2 Net asset value as of December 31, 2018. Assets
under management (“AUM”), as reported, may include notional assets,
assets serviced, gross assets and other types of non-regulatory AUM. AUM
does not include Vega Investment Managers, which was transferred to
Natixis Wealth Management in December 2018.

Before investing, consider the fund’s investment objectives, risks,
charges, and expenses. Please visit or call (800)
225-5478 for a prospectus and a summary prospectus, if available,
containing this and other information. Read it carefully.

Natixis Distribution, L.P. (fund distributor, member FINRA | SIPC)
and Loomis, Sayles & Company L.P. are affiliated.

Each year,
Morningstar recognizes an Outstanding Portfolio Manager, an individual
who has produced exceptional returns over the long term. Morningstar’s
manager research analysts conduct in-depth qualitative analyses in order
to select nominees and, subsequently, vote to determine the award
winner. To qualify for the award, the manager’s strategy must currently
earn a Morningstar® Analyst Rating™ of: Gold, which is a best-of-breed
managed portfolio that distinguishes itself across the pillars—such as
people, process, parent, performance, and price—and has garnered the
analysts’ highest level of conviction; or Silver, which is an offering
with advantages that outweigh the disadvantages across the pillars and
with sufficient level of analyst conviction to warrant a positive rating.

To be eligible for the Outstanding Portfolio Manager award, managers
must run investment strategies that are under Morningstar manager
research analyst coverage, which includes approximately 1,800 open-end
mutual funds, exchange-traded funds, separately managed accounts, or
collective investment trusts, and have received a Morningstar Analyst
Rating™ of Gold or Silver over the past 12 months. Nominees for this
award have delivered strong returns for investors over their careers.

Morningstar’s Manager Research Group consists of various wholly owned
subsidiaries of Morningstar, Inc. including, but not limited to,
Morningstar Research Services LLC. Analyst Ratings are subjective in
nature and should not be used as the sole basis for investment
decisions. Analyst Ratings are based on Morningstar’s Manager Research
Group’s current expectations about future events and therefore involve
unknown risks and uncertainties that may cause such expectations not to
occur or to differ significantly from what was expected. Analyst Ratings
are not guarantees nor should they be viewed as an assessment of a
fund’s or a fund’s or separately managed account’s underlying
securities’ creditworthiness. This press release is for informational
purposes only; references to securities or a separately managed account
investment strategy in this press release should not be considered an
offer or solicitation by Morningstar to buy or sell those funds.



Orla O’Brien
[email protected]

Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits




HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025


Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.


Cision View original content:

Continue Reading


Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer




DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:

Continue Reading


Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028



Continue Reading

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania